Meflin-Positive Cancer-Associated Fibroblasts Inhibit Pancreatic CarcinogenesisYasuyuki Mizutani, Masahide Takahashi, Tsutomu Fujii et al.|Cancer Research|2019Cited by 328
Pharmacologic conversion of cancer-associated fibroblasts from a protumor phenotype to an antitumor phenotype improves the sensitivity of pancreatic cancer to chemotherapeuticsTadashi Iida, Atsushi Enomoto, Yasuyuki Mizutani et al.|Oncogene|2022Cited by 68
Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosisYoshio Nakahara, Yoshinori Hasegawa, Naozumi Hashimoto et al.|European Respiratory Journal|2021Cited by 53
Development of a Novel Evaluation Method for Endoscopic Ultrasound-Guided Fine-Needle Biopsy in Pancreatic Diseases Using Artificial IntelligenceTakuya Ishikawa, Kazuhiro Hotta, Masato Hayakawa et al.|Diagnostics|2022Cited by 32
Safety and efficacy of MIKE-1 in patients with advanced pancreatic cancer: a study protocol for an open-label phase I/II investigator-initiated clinical trial based on a drug repositioning approach that reprograms the tumour stromaYasuyuki Mizutani, Mitsuhiro Fujishiro, Tadashi Iida et al.|BMC Cancer|2022Cited by 32